Welcome to our dedicated page for 111 news (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111 stock.
111, Inc. (NASDAQ: YI) is a tech-enabled healthcare platform company operating in China’s healthcare ecosystem. Its news flow is closely tied to its role in pharmaceutical product distribution, online healthcare services, and digital enablement of pharmacies and upstream partners. Company announcements often describe how 111, Inc. is reshaping the healthcare value chain by connecting consumers, pharmacies, and pharmaceutical companies through online and offline channels.
Investors following YI news can expect regular earnings and financial results updates, including unaudited quarterly results furnished on Form 6-K. These releases detail performance in the company’s B2B and B2C segments, trends in operating expenses, gross segment profit, and the use of non-GAAP measures such as non-GAAP income from operations and non-GAAP net income or loss. Management commentary in these announcements frequently addresses operational efficiency, cash flow, and progress on strategic initiatives.
Another key category of news involves strategic and operational developments. Recent disclosures describe a transition from an asset-heavy to an asset-light business model, including the divestiture of self-operated subsidiaries that have become warehouse partners. The company also reports on supply chain and logistics initiatives, such as the "MANTIANXING" project and the Kunpeng Network, which are intended to enhance fulfillment capabilities and efficiency.
111, Inc. also issues news about capital markets and compliance events, such as regaining compliance with Nasdaq listing requirements and changes to its ADS ratio. In addition, the company announces participation in investor events and fireside chats where management discusses earnings, strategic priorities, and the macroeconomic environment. For investors and observers of China’s digital healthcare and pharmacy distribution space, the YI news stream provides ongoing insight into the company’s financial performance, strategic direction, and technology-driven initiatives.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
111, Inc. (NASDAQ: YI) reported its unaudited financial results for Q4 and FY 2022, showcasing a strong growth trajectory. In Q4, net revenues reached RMB4.1 billion (US$601.4 million), up 19.9% YoY, while gross segment profit increased by 23.8%. The company's operational loss narrowed to RMB108.4 million (US$15.7 million), a slight increase from last year, but as a percentage of revenues, it improved to 2.61%. For FY 2022, revenues totaled RMB13.5 billion (US$2.0 billion), an 8.8% increase, with gross margin improving from 5.0% to 6.2%. The company achieved positive operating cash flow for the second consecutive quarter, indicating stronger operational efficiency.
111, Inc. (NASDAQ: YI) will report its unaudited financial results for Q4 and fiscal year 2022 on March 23, 2023, before U.S. market opens. The earnings conference call is scheduled for 7:30 AM ET the same day. 111, Inc. is a tech-enabled healthcare platform in China, connecting patients with healthcare services through its online pharmacy and virtual pharmacy network. The company also offers online healthcare services via its internet hospital, 1 Clinic, and provides a one-stop platform for pharmacies through 1 Medicine Marketplace.
On February 15, 2023, 111, Inc. (NASDAQ: YI) announced the launch of Hua Medicine's first official online flagship store during the HuaTangNing® Market Launch event. This collaboration aims to connect patients with healthcare services and enhance drug accessibility. The store will facilitate patient education on drug safety and provide innovative treatment information for diabetes. 111, Inc. plans to expand Hua Medicine's commercial presence while leveraging its digital tools for healthcare delivery. This milestone reinforces 111's position in China's tech-enabled healthcare sector, marking a crucial step toward innovative drug commercialization and patient management.
111, Inc. (NASDAQ: YI) reported its third-quarter financial results for 2022, achieving net revenues of RMB3.35 billion (US$470.8 million), a slight 0.1% increase year-over-year. Gross segment profit surged by 21.6%, while total operating expenses fell to RMB282.7 million (US$39.7 million), down from RMB341.4 million a year earlier. Non-GAAP loss from operations improved to RMB48.7 million (1.5% of net revenues), significantly better than the previous year's loss of RMB135.9 million. The company attributed its performance to enhanced operational efficiency amidst challenges from city lockdowns.
111, Inc. (NASDAQ: YI), a tech-enabled healthcare platform in China, will report its unaudited financial results for Q3 2022 on December 1, 2022, before U.S. market opens. The management will host an earnings call the same day at 7:30 AM EST. The company focuses on connecting patients with healthcare services through its online pharmacy, 1 Pharmacy, and internet hospital, 1 Clinic. It also provides a platform, 1 Medicine Marketplace, for pharmacies, enhancing drug accessibility and services across China.